Oricula Therapeutics, LLC, is a start-up biotechnology company with a mission to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging. Our first product will be the first medication to prevent hearing loss in patients undergoing treatment for serious infections with aminoglycoside antibiotics.
The company, founded in 2013, grew from research conducted at the University of Washington and funded through NIDCD and the NINDS Blueprint Neurotherapeutics Program (NIH BPN). The research led to patented findings that form the basis for further development of Oricula's first product. Oricula Therapeutics holds an exclusive license for the core patents and intellectual property from the University of Washington.
The company formed with a team that provides deep experience in hearing and neurological physiology, medical chemistry, drug development and business development.